Preoperative sarcopenia determinants in pancreatic cancer patients

G Carrara, N Pecorelli, F De Cobelli, G Cristel, A Damascelli, L Beretta, M Braga

Research output: Contribution to journalArticlepeer-review


Background & aims: Recent studies report that muscle depletion can impair short and long-term results after abdominal surgery. The aim of the present study is to quantify sarcopenia rate in patients undergoing pancreatic resection for cancer and to identify possible determinants of muscle waste. Methods: Total abdominal muscle area (TAMA) and visceral fat area (VFA) were measured by preoperative CT scan imaging at the level of the third lumbar vertebra in 273 patients undergoing pancreas resection for cancer. Demographics, preoperative parameters, and cancer stage were prospectively collected in our Institutional electronic database. An adjusted regression model was used to identify independent predictors for low TAMA. Results: 176 (64.5%) patients were sarcopenic, with only 52 of them showing weight loss > 10%. Patients with cancer stage II and III had lower TAMA compared to patients with stage I (p = 0.002). The magnitude of weight loss was inversely correlated with VFA (p = 0.001), while no correlation with TAMA was found. Multivariate analysis showed that cancer stage was an independent predictor of low TAMA. Patients aged over 75 had the highest probability of having both low TAMA (p = 0.031) and high VFA (p <0.0001). Conclusions: Most of patients undergoing oncologic pancreatic surgery are sarcopenic. Cancer stage was an independent determinant of sarcopenia while nutritional factors seem less important. An age of over 75 years was significantly correlated with both muscle compartment depletion and visceral fat increase. © 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism.
Original languageEnglish
Pages (from-to)1649-1653
Number of pages5
JournalClinical Nutrition
Issue number6
Publication statusPublished - 2017


Dive into the research topics of 'Preoperative sarcopenia determinants in pancreatic cancer patients'. Together they form a unique fingerprint.

Cite this